EMA Reduces Trial Requirements For Hemophilia Drugs
Executive SummaryNew guidance from the EMA says that data from patient disease registries can be used instead of clinical trials of previously untreated patients during the development of new treatments for hemophilia.
You may also be interested in...
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.